Cargando…

Targeting signaling pathways in prostate cancer: mechanisms and clinical trials

Prostate cancer (PCa) affects millions of men globally. Due to advances in understanding genomic landscapes and biological functions, the treatment of PCa continues to improve. Recently, various new classes of agents, which include next-generation androgen receptor (AR) signaling inhibitors (abirate...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Yundong, Xu, Weidong, Xiao, Yu-Tian, Huang, Haojie, Gu, Di, Ren, Shancheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9232569/ https://www.ncbi.nlm.nih.gov/pubmed/35750683 http://dx.doi.org/10.1038/s41392-022-01042-7

Ejemplares similares

Advances in landscape and related therapeutic targets of the prostate tumor microenvironment: Therapeutic targets of the prostate tumor microenvironment
por: Li, Duocai, et al.
Publicado: (2023)

Robotic-assisted versus laparoscopic radical prostatectomy for prostate cancer: the first separate systematic review and meta-analysis of randomised controlled trials and non-randomised studies
por: Ma, Jianglei, et al.
Publicado: (2023)

Cell-free DNA in the management of prostate cancer: Current status and future prospective
por: He, Wei, et al.
Publicado: (2023)

LINC00675 activates androgen receptor axis signaling pathway to promote castration-resistant prostate cancer progression
por: Yao, Mengfei, et al.
Publicado: (2020)

Assessing the safety and feasibility of neoadjuvant hormone and radiation therapy followed by robot-assisted radical prostatectomy for treating locally advanced prostate cancer: protocol for an open-label, dose-escalation, single-centre, phase I clinical trial
por: Xiao, Yu-Tian, et al.
Publicado: (2020)

Dual inhibition of AKT‐mTOR and AR signaling by targeting HDAC3 in PTEN‐ or SPOP‐mutated prostate cancer
por: Yan, Yuqian, et al.
Publicado: (2018)

Safety and Efficacy Study of Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer: Protocol of an Open-Label, Dose-Escalation, Single-Centre Phase I/II Clinical Trial
por: Zhao, Xianzhi, et al.
Publicado: (2022)

Intrinsic BET inhibitor resistance in prostate cancer caused by SPOP mutation-mediated BET protein stabilization
por: Zhang, Pingzhao, et al.
Publicado: (2017)

Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer
por: Wu, Changping, et al.
Publicado: (2015)

Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer
por: He, Yundong, et al.
Publicado: (2018)

Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials
por: Niu, Zhenyi, et al.
Publicado: (2022)

A combined signature of glycolysis and immune landscape predicts prognosis and therapeutic response in prostate cancer
por: Guo, Tao, et al.
Publicado: (2022)

Dysregulation of INF2-mediated mitochondrial fission in SPOP-mutated prostate cancer
por: Jin, Xiaofeng, et al.
Publicado: (2017)

Targeting signaling pathways in osteosarcoma: Mechanisms and clinical studies
por: Ji, Ziyu, et al.
Publicado: (2023)

Signaling pathways in cancer metabolism: mechanisms and therapeutic targets
por: You, Mengshu, et al.
Publicado: (2023)

Metagenomic and metatranscriptomic analysis of human prostate microbiota from patients with prostate cancer
por: Feng, Ye, et al.
Publicado: (2019)

Destruction of DNA‐Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG
por: Shao, Jingwei, et al.
Publicado: (2021)

Impact of Glutathione-S-Transferases (GST) Polymorphisms and Hypermethylation of Relevant Genes on Risk of Prostate Cancer Biochemical Recurrence: A Meta-Analysis
por: Chen, Rui, et al.
Publicado: (2013)

A noncanonical AR addiction drives enzalutamide resistance in prostate cancer
por: He, Yundong, et al.
Publicado: (2021)

Targeting integrin pathways: mechanisms and advances in therapy
por: Pang, Xiaocong, et al.
Publicado: (2023)

The older the better: The characteristic of localized prostate cancer in Chinese men
por: Wang, Haifeng, et al.
Publicado: (2015)

CircRPPH1 accelerates the proliferation and migration of bladder cancer via enhancing the STAT3 signaling pathway
por: Liu, Xiao, et al.
Publicado: (2023)

Clinical Significance of Hepsin and Underlying Signaling Pathways in Prostate Cancer
por: Lu, Lucy, et al.
Publicado: (2022)

Extraperitoneal tissue retraction technique: An effective assistant of extraperitoneal pure single-port robotic-assisted radical prostatectomy with the da Vinci Si surgical system
por: Ju, Guanqun, et al.
Publicado: (2022)

Research progress on drugs targeting the TGF-β signaling pathway in fibrotic diseases
por: Shi, Ning, et al.
Publicado: (2022)

Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer
por: He, Yundong, et al.
Publicado: (2016)

OTUD6A promotes prostate tumorigenesis via deubiquitinating Brg1 and AR
por: Fu, Xuhong, et al.
Publicado: (2022)

Enzalutamide: targeting the androgen signalling pathway in metastatic castration‐resistant prostate cancer
por: Schalken, Jack, et al.
Publicado: (2015)

Targeting multiple pro-apoptotic signaling pathways with curcumin in prostate cancer cells
por: Rivera, Mariela, et al.
Publicado: (2017)

Signaling pathways in macrophages: molecular mechanisms and therapeutic targets
por: Li, Ming, et al.
Publicado: (2023)

Clinical Implications of Hedgehog Pathway Signaling in Prostate Cancer
por: Suzman, Daniel L., et al.
Publicado: (2015)

Neurotensin and its receptors mediate neuroendocrine transdifferentiation in prostate cancer
por: Zhu, Shimiao, et al.
Publicado: (2019)

Downregulation of TET1 Promotes Glioma Cell Proliferation and Invasion by Targeting Wnt/β-Catenin Pathway
por: Ji, Jianwen, et al.
Publicado: (2021)

CBP/p300: Critical Co-Activators for Nuclear Steroid Hormone Receptors and Emerging Therapeutic Targets in Prostate and Breast Cancers
por: Waddell, Aaron R., et al.
Publicado: (2021)

AB077. Explore the clinical experience of robot-assisted laparoscopic radical prostatectomy for complex cases
por: Lu, Xiaojun, et al.
Publicado: (2018)

Percent free prostate-specific antigen for prostate cancer diagnosis in Chinese men with a PSA of 4.0–10.0 ng/mL: Results from the Chinese Prostate Cancer Consortium
por: Chen, Rui, et al.
Publicado: (2015)

Nomograms for predicting Gleason upgrading in a contemporary Chinese cohort receiving radical prostatectomy after extended prostate biopsy: development and internal validation
por: He, Biming, et al.
Publicado: (2016)

Targeting strategies for bone diseases: signaling pathways and clinical studies
por: Xu, Hao, et al.
Publicado: (2023)

Correction: Neurotensin and its receptors mediate neuroendocrine transdifferentiation in prostate cancer
por: Zhu, Shimiao, et al.
Publicado: (2019)

Targeting the p53 signaling pathway in cancers: Molecular mechanisms and clinical studies
por: Shen, Jinze, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hpq740g6hqrj5fghijo4ldursk